Camlipixant for IBS with diarrhea or mixed symptoms
Part of Digestive system clinical trials.
This study tests an investigational drug, camlipixant, to see if it can reduce belly pain and diarrhea or mixed bowel symptoms in adults with irritable bowel syndrome (IBS). If you've tried other IBS treatments without enough relief, this might be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with IBS (with diarrhea or mixed type) for at least 6 months.
- Your IBS symptoms are moderate to severe, including belly pain and abnormal stools.
- You have not tried more than two prior IBS treatments from the list of medication classes.
- You do not have other bowel diseases (like inflammatory bowel disease or celiac disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication called brenipatide can help people with IBS-diarrhea (IBS-D) reduce belly pain and loose stools. IBS-D is a condition where the intestines move too quickly, causing frequent diarrhea and discomfort.
This trial tests a new medicine called brenipatide to see if it can help people with IBS-C (irritable bowel syndrome with constipation). The study focuses on whether the drug reduces belly pain and improves bowel movements in people whose main symptom is hard or infrequent stools.
This trial tests whether an oral medicine (eluxadoline) can help children and teens with IBS-D, a condition that causes stomach pain and frequent loose stools. It’s a Phase 3 study, meaning it’s designed to confirm benefits and safety.
This trial tests a new treatment called SMT04 for people with irritable bowel syndrome (IBS), specifically the diarrhea or mixed types. It may help reduce symptoms like abdominal pain and changes in bowel habits.
This trial tests whether a synbiotic (a mix of probiotics and prebiotics) called Vivatlac can improve gut health in people with moderate to severe irritable bowel syndrome (IBS). If you have IBS and are not already taking probiotics or antibiotics, you may be able to join.
This trial tests whether a fecal microbiota transplantation (FMT), which transfers healthy bacteria from a donor into your gut, can reduce severe irritable bowel syndrome (IBS) symptoms. FMT is being studied as a possible new treatment for people with IBS that hasn't improved with other treatments.
Hear when a new Irritable Bowel Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.